Retrospective Real-World Study Assessing Treatment Patterns of Adult Patients with Moderate-to-Severe Psoriasis in the United States Initiating Advanced Therapies and Their Dispositions
Author(s)
Oluwakayode Adejoro, MD, MPH1, Valentine Laizet, MSc2, Shanti Neff-Baro, BA, MSc3.
1The Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA, 2Amaris Consulting, Health Economics and Market Access, Montreal, QC, Canada, 3Amaris Consulting, Health Economics and Market Access, Paris, France.
1The Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA, 2Amaris Consulting, Health Economics and Market Access, Montreal, QC, Canada, 3Amaris Consulting, Health Economics and Market Access, Paris, France.
Presentation Documents
OBJECTIVES: Psoriasis (PsO) is a chronic inflammatory skin condition that is often associated with various symptoms, signs and morbidity. Several advanced therapies (ATs) including tumor necrosis factor (TNF) inhibitors, interleukin (IL) inhibitors (e.g., IL-12/23, IL-23, IL-17), apremilast, deucravacitinib and biosimilars of TNF-inhibitors and IL-12/23 inhibitors are indicated for the treatment of moderate-to-severe PsO in the US. Treatment patterns and disposition of patients initiating ATs are not well understood.
METHODS: Patients were identified from the Merative® MarketScan® Commercial Claims Database between January 2013 and December 2023 as individuals with ≥ 2 PsO diagnoses initiating first-line (L1) AT with TNF-inhibitors, IL-inhibitors or apremilast. Treatment patterns were evaluated as sequences of monotherapies or combination therapies within 2 years following index date (defined as first prescription claim). Treatment discontinuation was defined as gaps in prescription refills of more than twice the labelled dosing interval or a change in prescription(s), including switches between biosimilars and originators. Time under L1 treatment was assessed using Kaplan-Meier methodology.
RESULTS: A total of 33,924 patients with moderate-to-severe PsO receiving ≥ 1 AT were identified. 52% were female and mean age was 45 years (standard deviation=11.2). Common comorbidities included psoriatic arthritis (20%) and hypertension (19%). For L1 monotherapies, 38% of patients received TNF-inhibitors, 32% apremilast, 27% IL-inhibitors; 3% received combination of ATs. Among L1 biologics, 99.8% were originators and 0.2% were biosimilars. The median time on L1 treatment was 8.5 months with 21% of patients censored prior to the end of the observation period.
CONCLUSIONS: Originator biologics and especially TNF-inhibitors originators were the predominant treatment choice for first-line moderate-to-severe psoriasis therapy. Half of the patients remained on first-line therapy for 8.5 months. The use of biosimilars was limited.
METHODS: Patients were identified from the Merative® MarketScan® Commercial Claims Database between January 2013 and December 2023 as individuals with ≥ 2 PsO diagnoses initiating first-line (L1) AT with TNF-inhibitors, IL-inhibitors or apremilast. Treatment patterns were evaluated as sequences of monotherapies or combination therapies within 2 years following index date (defined as first prescription claim). Treatment discontinuation was defined as gaps in prescription refills of more than twice the labelled dosing interval or a change in prescription(s), including switches between biosimilars and originators. Time under L1 treatment was assessed using Kaplan-Meier methodology.
RESULTS: A total of 33,924 patients with moderate-to-severe PsO receiving ≥ 1 AT were identified. 52% were female and mean age was 45 years (standard deviation=11.2). Common comorbidities included psoriatic arthritis (20%) and hypertension (19%). For L1 monotherapies, 38% of patients received TNF-inhibitors, 32% apremilast, 27% IL-inhibitors; 3% received combination of ATs. Among L1 biologics, 99.8% were originators and 0.2% were biosimilars. The median time on L1 treatment was 8.5 months with 21% of patients censored prior to the end of the observation period.
CONCLUSIONS: Originator biologics and especially TNF-inhibitors originators were the predominant treatment choice for first-line moderate-to-severe psoriasis therapy. Half of the patients remained on first-line therapy for 8.5 months. The use of biosimilars was limited.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD125
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), STA: Biologics & Biosimilars